Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in Germany
57 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleTrial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
- Where
- Berlin, Chemnitz, Dresden, Frankfurt Am Main, Hamburg, Heidelberg, Leipzig, Munich
- Age
- 18 years and over
- People
- 228 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-513122-27-00 - No phaseTaking peopleResponse Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer
- Where
- Berlin, Cologne, Dresden, Ulm, Würzburg
- Age
- 18 years and over
- People
- 48
- Run by
- Technische Universität Dresden
See details and how to joinNCT05652348 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Dresden, Essen, Frankfurt, Ulm, Würzburg
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 3Taking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
- Age
- 18 years and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - No phaseNot yet taking people in GermanyModulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
- Where
- Cologne
- Age
- 18 years and over
- People
- 88
- Run by
- University of Cologne
See details and how to joinNCT06414122 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Berlin
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 2Taking peopleZanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
- Where
- Berlin, Bielefeld, Dresden, Essen, Frankfurt, Göttingen, Hamburg, Herne, Jena, Mainz, Minden, München, Ravensburg, Regensburg, Ulm, Wolfsburg
- Age
- 18 years and over
- People
- 80
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07176312 · EU 2025-522718-22-00 - Phase 2/3Not yet taking people in Germany68Ga-FAPI-46 PET for imaging of gastrointestinal cancers: A prospective interventional single-arm clinical trial (FAPI-PET-GI)
- Where
- Essen, Muenster
- Age
- 18 years and over
- People
- 150
- Run by
- Universitaetsklinikum Essen AöR
See details and how to join2023-506030-70-00 - Phase 1/2Taking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00 - Phase 2Taking peoplePredicting Esophageal Cancer Borders Using PET-Imaging
- Where
- Heidelberg
- Age
- 18 years and over
- People
- 30
- Run by
- University Hospital Heidelberg
See details and how to joinNCT06408116 - No phaseNot yet taking people in GermanyA Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
- Where
- Leipzig
- Age
- 18 years and over
- People
- 266 worldwide
- Run by
- University Hospital, Antwerp
See details and how to joinNCT07455422 - No phaseTaking peopleThe MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Where
- Tübingen
- Age
- 18 years and over
- People
- 8,000 worldwide
- Run by
- UMC Utrecht
See details and how to joinNCT04075305 - Phase 3Taking peopleA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Where
- Amberg, Bielefeld, Dresden, Essen, Hanover, Heilbronn, Jena, Munich, Reutlingen
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06532006 · EU 2024-516633-12-00 - No phaseTaking peopleRegistry Platform Gastric/Esophageal Cancer (SAPHIR)
- Where
- Multiple Locations
- Age
- 18 years and over
- People
- 1,900
- Run by
- iOMEDICO AG
See details and how to joinNCT04290806 - Phase 1Taking peopleA Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
- Where
- Frankfurt, Hamburg, Leipzig, München
- Age
- 18 years and over
- People
- 18
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07059299 · EU 2024-519993-38-00 - No phaseTaking peopleClinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
- Where
- Erlangen
- Age
- 18 years and over
- People
- 200
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT04892849 - No phaseNot yet taking people in GermanyOmentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer
- Where
- Mainz
- Age
- 18 years and over
- People
- 654 worldwide
- Run by
- Amsterdam UMC
See details and how to joinNCT05180864 - No phaseNot yet taking people in GermanyRadiation-induced Toxicity of the Heart
- Where
- Dresden
- Age
- 18 years and over
- People
- 325
- Run by
- Technische Universität Dresden
See details and how to joinNCT06986291 - Phase 3Taking peoplePROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
- Where
- Dresden
- Age
- 18 years and over
- People
- 396 worldwide
- Run by
- University of Aarhus
See details and how to joinNCT05055648 - Phase 3Taking peopleHIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
- Where
- Aachen, Bielefeld, Bochum, Cologne, Deggendorf, Dresden, Erlangen, Frankfurt am Main, Frankfurt Am Main, Goettingen, Halle Saale, Hamburg, Herne, Karlsruhe, Leipzig, Ludwigsburg, Luebeck, Magdeburg, Mannheim, Muenster, Munich, Regensburg, Speyer, Witten, Wuerzburg
- Age
- 18 years to 75 years
- People
- 200
- Run by
- Krankenhaus Nordwest
See details and how to joinNCT04447352 · EU 2024-517300-10-01 - No phaseTaking peopleStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Where
- Hamburg
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767 - No phaseTaking peopleCIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
- Where
- Cologne, Münster
- Age
- 18 years and over
- People
- 100
- Run by
- Heinrich-Heine University, Duesseldorf
See details and how to joinNCT04455282 - Phase 2Not yet taking people in GermanyThe Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
- Where
- Berlin
- Age
- 18 years to 80 years
- People
- 264 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT06295094 - No phaseTaking peopleDistribution of Lymph Node Metastases in Esophageal Carcinoma
- Where
- Mainz
- Age
- 18 years and over
- People
- 5,000 worldwide
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT03222895 - No phaseTaking peopleFunctional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study
- Where
- Berlin
- Age
- 18 years and over
- People
- 48
- Run by
- Sebastian Zschaeck
See details and how to joinNCT06189898